Clindamycin Phosphate Injection Shortage: Supply Updates and Manufacturer Status
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
Clindamycin Phosphate Injection is currently facing supply challenges due to increased demand, with some manufacturers reporting unavailability until 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, ClindamycinPhosphate) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
Clindamycin Phosphate Injection, an anti-infective medication, is currently listed as being in shortage. This shortage affects several presentations of the drug, including brand names CLINDAMYCIN PHOSPHATE, CLINDAMYCIN IN 5 PERCENT DEXTROSE, and CLINDAMYCIN. The medication is administered in an injection dosage form. This shortage was first posted on March 21, 2023, and was last updated on February 2, 2026.
Which Manufacturers Are Affected
Several manufacturers are involved in the supply of Clindamycin Phosphate Injection, with varying levels of availability:
- Baxter Healthcare (888-229-0001):
- Unavailable: 300 mg/50 mL (NDC 0338-9549-50), 900 mg/50 mL (NDC 0338-9553-50), and 600 mg/50 mL (NDC 0338-3612-50). Estimated recovery for these is March 2026.
- Limited Availability: 900 mg/50 mL (NDC 0338-3814-50). Recovery date is currently TBD.
- Available: Certain 300 mg/50 mL presentations (NDC 0338-3410-50 and 0338-9545-50).
- Sandoz Inc. (800-525-8747):
- Available: Multiple presentations including 12 mg/1 mL, 18 mg/1 mL, and 6 mg/1 mL in various containers (some under the Civica Label).
- Sagent Pharmaceuticals (866-625-1618):
- Available: 150 mg/1 mL presentations (NDC 25021-115-06, 25021-115-04, 25021-115-02).
Why There's a Shortage
According to the FDA, the primary reason for the current shortage is a demand increase for the drug.
What Patients Should Do
If you or a loved one are prescribed Clindamycin Phosphate Injection, please consider the following steps:
- Consult Your Healthcare Provider: Speak with your doctor regarding your treatment plan and any concerns about medication availability.
- Talk to Your Pharmacist: Pharmacists often have the most up-to-date information on local stock and can coordinate with providers if a specific presentation is unavailable.
- Contact Manufacturers: For specific questions regarding supply timelines for certain NDCs, you may contact the manufacturers directly using the phone numbers provided above.
Disclaimer: Patients should always consult their healthcare provider for medical advice and treatment options. Do not alter your medication regimen without professional medical guidance.
Source
Information provided by the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category